Prospera Financial Services’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10,000
| Closed | -$166K | – | 1142 |
|
|
2024
Q1 | $166K | Hold |
10,000
| – | – | 0.01% | 1052 |
|
|
2023
Q4 | $135K | Hold |
10,000
| – | – | ﹤0.01% | 1016 |
|
|
2023
Q3 | $110K | Hold |
10,000
| – | – | ﹤0.01% | 973 |
|
|
2023
Q2 | $129K | Hold |
10,000
| – | – | ﹤0.01% | 971 |
|
|
2023
Q1 | $120K | Hold |
10,000
| – | – | ﹤0.01% | 928 |
|
|
2022
Q4 | $137K | Buy |
+10,000
| New | +$137K | 0.01% | 860 |
|
|
2022
Q2 | – | Sell |
-10,000
| Closed | -$180K | – | 1782 |
|
|
2022
Q1 | $180K | Hold |
10,000
| – | – | 0.01% | 912 |
|
|
2021
Q4 | $238K | Buy |
+10,000
| New | +$238K | 0.01% | 782 |
|